GlassScriptPhysician profile
Payal S Patel
NPI 1962706317
$1,177.67
in general payments reported to CMS, 2019-2025
19 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.91 · 2020: $113 · 2021: $77.74 · 2022: $153 · 2023: $254 · 2024: $252 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697 · Travel and Lodging: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.01 |
| Travel and Lodging | $125.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $186.64 | 2024-2025 | |
| Abbott Laboratories | $180.86 | 2023-2025 | Cardiomems, Freestyle Libre 3 |
| Abbvie INC. | $154.88 | 2021-2025 | |
| Ascendis Pharma Endocrinology INC | $93.79 | 2022 | |
| Xeris Pharmaceuticals, INC. | $71.44 | 2023-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $62.98 | 2020-2023 | Baqsimi |
| Novo Nordisk INC | $54.07 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $53.20 | 2020-2024 | |
| Medtronic, INC. | $48.33 | 2021-2023 | Minimed 780g |
| Tolmar, INC. | $47.38 | 2023-2024 | |
| Eton Pharmaceuticals, INC. | $39.86 | 2023-2025 | Alkindi, Khindivi, Increlex |
| Arbor Pharmaceuticals, INC. | $31.56 | 2020 | |
| Medtronic Minimed, INC. | $26.51 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $25.72 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.85 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $22.36 | 2023 | Triptodur |
| Sun Pharmaceutical Industries INC. | $21.49 | 2020 | |
| Zealand Pharma US, INC. | $18.61 | 2021 | |
| Ascensia Diabetes Care US INC. | $15.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.